Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus NATURETIN 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus NATURETIN 5.
HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs NATURETIN-5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting arteriolar vasodilator that reduces peripheral vascular resistance via relaxation of vascular smooth muscle, possibly by interfering with calcium transport. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, and reducing plasma volume.
Thiazide diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, decreasing sodium and water reabsorption and reducing intravascular volume and blood pressure.
Initially one capsule (25 mg hydralazine/25 mg hydrochlorothiazide, or 50 mg hydralazine/50 mg hydrochlorothiazide) twice daily, increase as needed to a maximum of 200 mg hydralazine/200 mg hydrochlorothiazide daily.
5 mg orally once daily.
None Documented
None Documented
Hydralazine: 2-8 hours (terminal, prolonged in renal impairment; acetylator phenotype affects clearance; slow acetylators have 2-fold longer half-life). Hydrochlorothiazide: 6-15 hours (terminal, prolonged in renal impairment; clinically relevant for once-daily dosing).
Terminal elimination half-life is approximately 18-24 hours; clinically, this supports once-daily dosing and requires renal function monitoring.
Hydralazine: 90% renal (primarily as metabolites, 10-15% unchanged); Hydrochlorothiazide: >95% renal (unchanged). Biliary/fecal: negligible for both.
Primarily renal (70-80% as unchanged drug); the remainder (20-30%) is eliminated via biliary/fecal routes.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic